Mabthera, Avastin, and Humira similars also saw a sharp rise in market share new product addition effect. The share of biosimilar products in the domestic market is rapidly expanding.

Enbrel biosimilars Etanercept increased its market share from 12% in 2018 to 44% last year. Herceptin similars also expanded from 9% to 37% during the same period.

◆Eucept and Remaloce, Enbrel similar, had a 44% market share with sales of 8.1 billion won last year

According to IQVIA, a pharmaceutical market research institute, on the 10th, the market for Etanercept ingredient treatment last year was 18.2 billion won. Pfizer Enbrel, the original product, recorded 10.1 billion won and Enbre